Last $3.17 USD
Change Today -0.06 / -1.86%
Volume 13.9K
WGBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Snapshot

Open
$3.28
Previous Close
$3.23
Day High
$3.30
Day Low
$3.10
52 Week High
02/26/14 - $30.00
52 Week Low
12/31/14 - $2.85
Market Cap
18.6M
Average Volume 10 Days
15.6K
EPS TTM
$-31.72
Shares Outstanding
5.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WAFERGEN BIO-SYSTEMS INC (WGBS)

Related News

No related news articles were found.

wafergen bio-systems inc (WGBS) Related Businessweek News

No Related Businessweek News Found

wafergen bio-systems inc (WGBS) Details

WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific. The company offers SmartChip Real-Time PCR system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of real-time polymerase chain reaction (PCR). Its SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample Nanodispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. The company also provides SmartChip Target Enrichment system for performing a sample preparation step prior to targeted next-generation sequencing (NGS); and Apollo 324TM System, a walk-away automation platform that offers DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on NGS platforms. The company focuses on providing its products to researchers who perform genetic analysis, primarily at pharmaceutical and biotech companies, academic and private research centers, and diagnostics companies involved in biomarker discovery and genetic research. WaferGen Bio-systems, Inc. was founded in 2002 and is headquartered in Fremont, California.

44 Employees
Last Reported Date: 11/12/14
Founded in 2002

wafergen bio-systems inc (WGBS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $720.0K
Compensation as of Fiscal Year 2013.

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Bio-systems, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 02:45 PM

WaferGen Bio-systems, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 02:45 PM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.

WaferGen Bio-Systems, Inc. Announces Unaudited Consolidated Earnings and Operating Results for the Third Quarter and Nine Months Ended September 30, 2014; Reaffirms Earnings Guidance for the Full Year 2014; Appoints Keith Warner as Chief Operating Officer and Michael P. Henighan as Chief Financial Officer

WaferGen Bio-systems, Inc. announced unaudited consolidated earnings and operating results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total Revenues were $1,250,201 against $389,547 a year ago. The increase total revenue is primarily due to revenue from the Apollo 324TM library prep products acquired in early 2014, which accounted for 46% of product revenue in the third quarter of 2014. Operating loss was $3,128,194 against $3,228,005 a year ago. Net loss before provision for income taxes was $2,780,535 against $10,807,802 a year ago. Net loss attributable to common stockholders was $2,780,535 against $12,246,825 a year ago. Net loss per share basic and diluted was $1.02 against $43.51 a year ago. The lower net loss was primarily due to a reduction in non-operating expenses of $7.9 million, mainly due to the absence of $7.5 million in non-cash charges related to capital restructuring in 2013. For the nine months, the company reported total Revenues were $4,389,622 against $814,282 a year ago. Operating loss was $8,931,669 against $7,788,330 a year ago. Net loss before provision for income taxes was $7,426,462 against $17,749,806 a year ago. Net loss attributable to common stockholders was $7,429,562 against $22,097,341 a year ago. Net loss per share basic and diluted was $4.87 against $180.16 a year ago. The company announced the appointment of Keith Warner as Chief Operating Officer and Michael P. Henighan as Chief Financial Officer, adding seasoned executives to senior management team. The revenue guidance for the full year is in excess of $6 million for 2014, unchanged from prior guidance.

WaferGen Bio-systems, Inc., Q3 2014 Earnings Call, Nov 07, 2014

WaferGen Bio-systems, Inc., Q3 2014 Earnings Call, Nov 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $3.17 USD -0.06

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $3.42 USD -0.07
Exiqon A/S kr8.00 DKK +0.10
NanoString Technologies Inc $12.86 USD -0.16
Pacific Biosciences of California Inc $8.26 USD +0.23
Sequenom Inc $3.65 USD -0.04
View Industry Companies
 

Industry Analysis

WGBS

Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit www.wafergen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.